Impact of HPV immunization on the detection of cervical disease

References

• Arbyn M, Bryant A, Beutels P, et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors (Protocol). Cochrane Database Syst Rev 2011;4
   PubMedGoogle Scholar
• Malagon T, Drolet M, Boily M, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012;12(10):781-9
   PubMed Web of Science ®Google Scholar
• Newall AT, Brotherton JML, Quinn HE, et al. Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia. Clin Infect Dis 2008;46(11):1647-55
   PubMedGoogle Scholar
• Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007;370(9590):890-907
   PubMed Web of Science ®Google Scholar
• Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189(1):12-19
   PubMed Web of Science ®Google Scholar
• Chase DM, Kalouyan M, DiSaia PJ. Colposcopy to evaluate abnormal cervical cytology in 2008. Am J Obstet Gynaecol 2009;200(5):472-80
   PubMed Web of Science ®Google Scholar
• Bosch FX, Lorincz A, Munoz N, et al. The causal relationship between human papillomavirus and cervical cancer. J Clin Pathol 2002;55(4):244-65
   PubMed Web of Science ®Google Scholar
• IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human Papillomavirus. In: A review of human carcinogens. Part B: Biological Agents. International Agency for Research on Cancer, Lyon, France 2012;255-95
   Google Scholar
• Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348(6):518-27
   PubMed Web of Science ®Google Scholar
• Munoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010;102(5):325-39
   PubMed Web of Science ®Google Scholar
• NHS Quality Improvement Scotland. Scottish Cervical Screening Programme 2006 Follow-up. 2006. Available from: http://www.healthcareimprovementscotland.org/previous_resources/archived/scottish_cervical_screening_pr.aspx [Last accessed 13 December 2012]
   Google Scholar
• Brotherton JML, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011;377(9783):2085-92
   PubMed Web of Science ®Google Scholar
• Luesley D, Leeson S. Colposcopy and Programme Management: Guidelines for the NHS Cervical Screening Programme (2nd edition). 2010. Available from: http://www.cancerscreening.nhs.uk/cervical/publications/nhscsp20.pdf [Last accessed 11 December 2012]
   Google Scholar
• Massad LS, Jeronimo J, Schiffman M. Interobserver agreement in the assessment of components of colposcopic grading. Obstet Gynecol 2008;111(6):1279-84
   PubMedGoogle Scholar
• Kitchener HC, Almonte M, Gilham C, et al. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess 2009;13(51):1-150
   PubMed Web of Science ®Google Scholar
• Mesher D, Szarewski A, Cadman L, et al. Long term follow up of cervical disease in women screened by cytology and HPV testing: results from the HART study. Br J Cancer 2010;102(9):1405-10
   PubMed Web of Science ®Google Scholar
• Porras C, Wentzensen N, Rodriguez AC, et al. Switch from cytology-based to human papillomavirus test-based cervical screening: implications for cytology. IJC 2012;130(8):1879-87
   Google Scholar
• Ronco G, Dillner J, Elfstrom M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2013;383(9916):524-32
   PubMedGoogle Scholar
• Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;337:a1754
   PubMed Web of Science ®Google Scholar
• Green J, Berrington de Gonzalez A, Sweetland S, et al. Risk factors for adenocarcinoma and squamous cell carcinoma of the cervix in women aged 20-44 years: the UK National Case-Control Study of Cervical Cancer. Br J Cancer 2003;89(11):2078-86
   PubMedGoogle Scholar
• Gasparini R, Panatto D. Cervical cancer: From Hippocrates through Rigoni-Stern to zur Hausen. Vaccine 2009;27(Suppl 1):A4-5
   PubMedGoogle Scholar
• Cuschieri K, Brewster DH, Williams ARW, et al. Distribution of HPV types associated with cervical cancers in Scotland and implications for the impact of HPV vaccines. Br J Cancer 2010;102(5):930-2
   PubMedGoogle Scholar
• Powell SE, Hariri S, Steinau M, et al. Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine 2012;31(1):109-13
   PubMed Web of Science ®Google Scholar
• The FUTUREI/II Study Group. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010;341:c3493
   PubMedGoogle Scholar
• Ball SLR, Winder DM, Vaughan K, et al. Analyses of Human Papillomavirus Genotypes and Viral Loads in Anogenital Warts. J Med Virol 2011;83(8):345-1350
   Google Scholar
• Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011;11(1):39-44
   PubMed Web of Science ®Google Scholar
• Leval A, Herweijer E, Arnheim-Dahlstrom L, et al. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis 2012;206(6):860-8
   PubMed Web of Science ®Google Scholar
• Rodriguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008;100(7):513-17
   PubMedGoogle Scholar
• The GlaxoSmithKlineVaccineHPV-007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvant vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009;374(9706):1975-85
   PubMedGoogle Scholar
• Govan VA. A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil®). Ther Clin Risk Manag 2008;4(1):65-70
   PubMedGoogle Scholar
• Arends MJ, Buckley CH, Wells M. Aetiology, pathogenesis, and pathology of cervical neoplasia. J Clin Pathol 1998;51(2):96-103
   PubMed Web of Science ®Google Scholar
• Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012;30(Suppl 5):F123-38
   PubMed Web of Science ®Google Scholar
• Cervical Cancer Action. Progress in Cervical Cancer Prevention: the CCA Report Card. 2012. Available from: http://www.cervicalcanceraction.org/pubs/CCA_reportcard_low-res.pdf [Last accessed 6 January 2014]
   Google Scholar
• GAVI Alliance. Millions of girls in developing countries to be protected against cervical cancer thanks to new HPV vaccine deals. 2013. Available from: http://www.gavialliance.org/library/news/press-releases/2013/hpv-price-announcement/# [Last accessed 23 July 2013]
   Google Scholar
• La Torre G, de Waure C, Chiaradia G, et al. HPV vaccine efficacy in preventing persistent cervical HPV infection: a systematic review and meta-analysis. Vaccine 2007;25(50):8352-8
   PubMedGoogle Scholar
• Peto J, Gilham C, Deacon J, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester Cohort. Br J Cancer 2004;91(5):942-53
   PubMed Web of Science ®Google Scholar
• Roteli-Martins CM, Naud P, De Borba P, et al. Sustained immunogenicity and efficacy of the HPV 16/18 AS04-adjuvanted vaccine: Up to 8.4 years of follow up. Hum Vaccin Immunother 2012;8(3):390-7
   PubMed Web of Science ®Google Scholar
• Luna J. HPV6/11/16/18 vaccine efficacy in women 24 to 45: follow-up through 6.3 years post-vaccination. EUROGIN 2013; OC 17-13
   Google Scholar
• Smith MA, Canfell K, Brotherton JML, et al. The predicted impact of vaccination on human papillomavirus infections in Australia. Int J Cancer 2008;123(8):1854-63
   PubMed Web of Science ®Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases. N Engl J Med 2007;356(19):1928-43
   PubMed Web of Science ®Google Scholar
• The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. New Engl J Med 2007;256(19):1915-27
   Google Scholar
• Department of Health. The “Green Book” chapter on human papillomavirus (HPV). 2012. Available from: https://www.wp.dh.gov.uk/immunisation/files/2012/07/Green-Book-Chapter-18a-v2_0.pdf [Last accessed 10 January 2013]
   Google Scholar
• Health Protection Scotland. Immunisation and Vaccine Preventable Disease. 2012. Available from: http://www.hps.scot.nhs.uk/immvax/hpv.aspx [Last accessed 13 December 2012]
   Google Scholar
• Information Services Division. HPV Immunisation Uptake Rates: school Year 2011/12. 2012. Available from: http://www.isdscotland.org/Health-Topics/Child-Health/Publications/2012-09-25/2012-09-25-HPV-Uptake-Report.pdf?85877627135 [Last accessed 13 December 2012]
   Google Scholar
• Health Protection Scotland. Human Papillomavirus (HPV) Immunisation Programme 2012/13. 2012. Available from: http://www.hps.scot.nhs.uk/ewr/article.aspx [Last accessed 18 December 2012]
   Google Scholar
• Jeronimo J, Massad LS, Schiffman M. Visual appearance of the uterine cervix: correlation with human papillomavirus detection and type. Am J Obstet Gynaecol 2007;197(1):47; e1-8
   PubMed Web of Science ®Google Scholar
• Louwers JA, Zaal A, Kocken M, et al. Dynamic spectral imaging colposcopy: higher sensitivity for detection of premalignant cervical lesions. BJOG 2010;118(3):309-18
   PubMedGoogle Scholar
• Zaal A, Louwers JA, Berkhof J, et al. Agreement between colposcopic impression and histological diagnosis among human papillomavirus type 16-positive women: a clinical trial using dynamic spectral imaging colposcopy. BJOG 2012;119(5):537-44
   PubMed Web of Science ®Google Scholar
• Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013;346:f2032
   PubMed Web of Science ®Google Scholar
• Brill D. Australia launches national scheme to vaccinate boys against HPV. BMJ 2013;346:f924
   PubMedGoogle Scholar
• Dorell C, Stokely S, Yankey D, et al. National and state vaccination coverage among adolescents aged 13-17 years. MMWR Morb Mortal Wkly Rep 2012;61(34):671-7
   PubMedGoogle Scholar
• Bauer HM, Wright G, Chow J. Evidence of human papillomavirus effectiveness in reducing genital warts: an analysis of california public family planning administrative claims data, 2007-2010. Am J Public Health 2012;102(5):833-5
   PubMed Web of Science ®Google Scholar
• Gertig D, Brotherton J, Budd A, et al. Impact of a population-based HPV vaccination program on cervical abnormalities in Victoria, Australia. EUROGIN 2013; SS 22-5
   Google Scholar
• Hariri S, Unger E, Powell S, et al. The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions. Cancer Causes Control 2012;23(2):281-8
   PubMedGoogle Scholar
• Tabrizi SN, Brotherton JML, Kaldor JM, et al. Human papillomavirus prevalence following a national vaccination program. EUROGIN 2013;SS:22-1
   Google Scholar
• Munro A, Cruickshank M, Cotton S, et al. The impact of HPV genotypes on colposcopic features in women offered HPV immunisation. BSCCP 2013; O-4
   Google Scholar
• Franco EL, Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 2008;26(Suppl 1):A16-23
   PubMedGoogle Scholar
• Van de Velde N, Boily M, Drolet M, et al. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. J Natl Cancer Inst 2012;104(22):1712-23
   PubMed Web of Science ®Google Scholar
• Pollock K, Potts A, Love J, et al. Early effect of the HPV bivalent vaccine on high risk HPV prevalence and high-grade cervical abnormalities in Scotland. EUROGIN 2013
   Google Scholar